

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2025

Plano Pharmaceuticals Inc. and Orion Asset Management, LLC

Grayslake

I. Development Assistance Agreements Awarded in 2025

	Assistance Amount	Agreement Number
EDGE Tax Credit	0.00	25 ZCA1078

II. Organization/Project Site Information

Chief Officer or authorized designee	Vedat Demirci
Title	Founder
Address	177 Huntington Avenue
	17th Floor #1880
	Boston, MA 2115
	USA
Phone	773-726-1154
E-mail	vedat.demirci@planopharmaceuticals.com
Standard Industrial Classification Number (SIC#)	2834
North American Industry Classification System (NAICS)	325412

III. Did the recipient's use of the State Funding reduce employment at any other site in Illinois? No

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2025

Plano Pharmaceuticals Inc. and Orion Asset Management, LLC

Grayslake

IV. Job Creation and Retention Data

Program Type EDGE Tax Credit

Agreement Number 25 ZCA1078

Assistance Amount 0.00

Report Header Definitions	
Wages	Average Annual Salary by Classifications
Full-Time	Permanent Full-Time
+/-	Gain or (Loss)

Number of Employees At the Time of Application

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Management / R&D	0.00	0	0	0	0
Totals:		0	0	0	0

Number of Employees As of the Date of the Report (12/31/2025)

Job Classification	Avg Annual Salary	Positions	Full-Time	+/-	Part-Time	+/-	Temporary	+/-
Management / R&D	0.00	0	0	0	0	0	0	0
Totals:		0	0	0	0	0	0	0

Number of Jobs Stated in the Agreement that would be Created at the Site as a Result of Assistance

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Management / R&D	80000.00	6	6	0	0
Totals:		6	6	0	0

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2025

Plano Pharmaceuticals Inc. and Orion Asset Management, LLC

Grayslake

Number of Jobs Stated in the Agreement that would be Retained at the Site as a Result of Assistance

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Management / R&D	80000.00	6	6	0	0
Totals:		6	6	0	0

Number of Full-Time Permanent Employees Anticipated To Be Hired at this Site on 12/31/2025

Job Classification	Anticipated Starting Dates	Number of Positions to be Hired in this Category	Average Annual Wage per New Employee	Total New Payroll to be Created
Management / R&D	12/31/2028	6	\$80,000.00	\$480,000.00
Totals:		6		\$480,000.00

Job Creation Data Explanatory Notes

If the change (gain/loss) in the number of full-time permanent employees as of the date of the report plus the number of full-time permanent employees anticipated to be hired after date of the report does not equal the number of full-time permanent employees stated in the Agreement that would be created at the site as a result of the assistance, then please explain why not:

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2025

Plano Pharmaceuticals Inc. and Orion Asset Management, LLC

Grayslake

I, Vedat DEMIRCI, as the chief officer or authorized designee of the recipient, verify that the information in the progress report contains no knowing misrepresentation of material facts upon which eligibility for development assistance is based. I further certify that, to the best of my knowledge, the recipient is in compliance with the development assistance agreement(s) between, or on behalf of, the recipient and the Illinois Department of Commerce and Economic Opportunity and/or the Illinois Department of Transportation and/or the office of the Illinois State Treasurer

Signature on File

Signature

4/3/2026

Date

CEO

Title